Integrated proprietary R&D engine anchored around our deep understanding of tumor immunology, continuously driving the discovery and development of innovative next-generation immunotherapies.
We have established a comprehensive pipeline of over ten drug candidates targeting critical innate and adaptive immune checkpoints, including six in clinical stage, one in IND stage and one in IND-enabling stage, with eight ongoing clinical programs, five IND/IND-enabling-stage programs, and multiple in discovery and preclinical stage.
